SCHEMBL17843945

SCHEMBL17843945

CCc1ccc(N(CC(C)C)S(=O)(=O)c2ccc(NCc3ccncc3)c([N+](=O)[O-])c2)cc1

nearest known ligand 0.56

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
RORC P51449 19/20 0.56
IL17A Q16552 4/20 0.56
LMNA P02545 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17843941 0.86 RORC (0.58) RORCIL17A
SCHEMBL17843355 0.84 RORC (0.77) RORCIL17A
SCHEMBL17847313 0.80 MEN1 (0.53) RORCIL17A
SCHEMBL17843892 0.80 RORC (0.73) RORCIL17A
SCHEMBL17843840 0.80 RORC (0.76) RORCIL17A
SCHEMBL17859148 0.79 RORC (0.61) RORCIL17A
SCHEMBL20677639 0.79 RORC (0.61) RORCIL17A
SCHEMBL17843931 0.79 RORC (0.62) RORCIL17A
SCHEMBL17843345 0.78 RORC (0.49) RORCIL17A
SCHEMBL17843833 0.78 VCAM1 (0.59) RORCIL17A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107257791-B Benzimidazole sulfonamide derivatives as inverse agonists of the retinoid-related orphan receptor gamma ROR gamma (t) 盖尔德马研究及发展公司 2021-06-11 CN disclosed
US-10618890-B2 Benzimidazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR gamma (T)) GALDERMA RESEARCH & DEVELOPMENT (FR) 2020-04-14 US disclosed
US-20190071433-A1 BENZIMIDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) GALDERMA RESEARCH & DEVELOPMENT (FR) 2019-03-07 US disclosed
EP-3233838-B1 BENZIMIDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) GALDERMA RES & DEV (FR) 2019-01-30 EP disclosed
EP-3233838-B1 BENZIMIDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) GALDERMA RES & DEV (FR) 2019-01-30 EP disclosed
EP-3233838-A1 BENZIMIDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) Galderma Research & Development (FR) 2017-10-25 EP disclosed
WO-2016097393-A1 BENZIMIDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) GALDERMA RESEARCH & DEVELOPMENT (FR) 2016-06-23 WO disclosed
WO-2016097393-A1 BENZIMIDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) GALDERMA RESEARCH & DEVELOPMENT (FR) 2016-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190071433-A1 BENZIMIDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) RORA, RORB, RORC RORC 3/4885IL17A 137/4885LMNA 4279/4885
US-10618890-B2 Benzimidazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR gamma (T)) RORA, RORB, RORC RORC 3/4885IL17A 137/4885LMNA 4279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.